Back to results
US 2001/0027185 A1Published application
Methods and compositions for treating inflammatory response
AssigneeUniversity of Virginia Patent Foundation
InventorsJoel M. Linden, Gail W. Sullivan, Ian J. Sarembock, Timothy MacDonald, Mark Okusa, Irving L. Kron, W. Michael Scheld
Life of this patent
Estimating the term…
Abstract
Compounds and methods are provided to treat inflammatory conditions with certain A2A adenosine receptor antagonists.
Claims44
A compound of the formula (I):
- 7
- wherein (a) each R is individually hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, phenyl or phenyl(C1-C3)-alkyl;
- (b) X is —CH2OH, —CO2R2, -OC(O)R2 or C(O)NR3R4;
- (c) each of R2, R3 and R4 is individually H, C1-6-alkyl;
- C1-6-alkyl substituted with 1-3 C1-6-alkoxy, C3-C7 cycloalkyl, C1-6-alkylthio, halogen, hydroxy, amino, mono(C1-6-alkyl)amino, di(C1-6-alkyl)amino, or C6-10-aryl, wherein aryl may be substituted with 1-3 halogen, C1-6-alkyl, hydroxy, amino, mono(C1-6-alkyl)amino, or di(C1-6-alkyl)amino;
- C6-10-aryl;
- or C6-10-aryl substituted with 1-3 halogen, hydroxy, amino, mono(C1-6-alkyl)amino, di(C1-6-alkyl)amino or C1-6-alkyl;
- (d) R1 is (X-(Z)-)n[(C3-C10)cycloalkyl]-(Z′)- wherein Z and Z′ are individually (C1-C6)alkyl, optionally interrupted by 1-3 S or noperoxide O, or is absent, and n is 1-3;
- or a pharmaceutically acceptable salt thereof.
6 more elements
Methyl-4-(3-{9-[(4S,5S,2R, 3R)-5-(N-ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]-6-aminopurin-2-yl)}prop-2-ynyl)cyclohexane-carboxylate.
A therapeutic method to inhibit an inflammatory response comprising administering to a mammal in need of said therapy, an effective anti-inflammatory amount of a compound of formula (I):
- 8
- wherein (a) each R is individually hydrogen, C1-C6 alkyl C3-C7 cycloalkyl, phenyl or phenyl(C1-C3)-alkyl;
- (b) X is —CH2OH, —CO2R2, —OC(O)R2 or C(O)NR3R4;
- (c) each of R2, R3 and R4 is individually H, C1-6-alkyl;
- C1-6-alkyl substituted with 1-3 C1-6-alkoxy, C3-C7-cycloalkyl, C1-6-alkylthio, halogen, hydroxy, amino, mono(C1-6-alkyl)amino, di(C1-6-alkyl)amino, or C6-10 -aryl, wherein aryl may be substituted with 1-3 halogen, C1-6-alkyl, hydroxy, amino, mono(C1-6-alkyl)amino, or di(C1-6-alkyl)amino;
- C6-10-aryl;
- or C6-10-aryl substituted with 1-3 halogen, hydroxy, amino, mono(C1-6-alkyl)amino, di(C1-6-alkyl)amino or C1-6-alkyl;
- (d) each of R3 and R4 is individually hydrogen, C3-7-cycloalkyl, or any of the meanings of R2;
- and
- (e) R1is (X-(Z)-)n[(C3-Cl10)cycloalkyl]-(Z′)- wherein Z and Z′ are individually (C1-C6)alkyl, optionally interrupted by 1-3 S or noperoxide O, or is absent, and n is 1-3;
- or a pharmaceutically acceptable salt thereof.
8 more elements
Dependencies are inferred from the claim text.